ASND vs. RVMD: Ascendis Pharma vs. Revolution Medicines Stock Comparison

Company Profile

Ascendis Pharma (ASND) and Revolution Medicines (RVMD) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Revolution Medicines (RVMD) has an aggressive beta of 1.42, indicating higher sensitivity to broad-market moves, while Ascendis Pharma (ASND) is defensive at 0.38 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Ascendis Pharma (ASND) reports 118.78%, ranking against industry peers normally.

Ascendis Pharma (ASND) at 70.85% converts revenue to bottom-line profit above its industry’s benchmark range, while Revolution Medicines (RVMD) at 0.00% keeps roughly the typical share for its industry.

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Ascendis Pharma (ASND) reports 64.98%, ranking against industry peers normally.

Profitability Metrics

Growth

Only one side can be read here: Ascendis Pharma (ASND) reports revenue growth of 98.03%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Neither Ascendis Pharma (ASND) nor Revolution Medicines (RVMD) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both Ascendis Pharma (ASND) at 2.99 and Revolution Medicines (RVMD) at 8.36 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both Ascendis Pharma (ASND) at 0.31 and Revolution Medicines (RVMD) at 0.50 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Ascendis Pharma (ASND) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Ascendis Pharma (ASND) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Ascendis Pharma (ASND) trades at 19.68 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

Ascendis Pharma (ASND) at 16.14 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 210.51 clears its benchmark range — RVMD looks notably rich on sales.

Both look rich against book: Ascendis Pharma (ASND) at 10.45 sits in the upper P/B ratio quartile, and Revolution Medicines (RVMD) at 17.31 prices even higher, above its industry range.

Valuation Metrics